Ralph Doyle resumes & CV records
Resumes
Ralph Doyle
Ralph T Doyle, 753244 Oceanic Bay Dr, Southport, NC 28461
Ralph Doyle Phones & Addresses
Southport, NC
Millsboro, DE
21 Mountain Ave, Maplewood, NJ 07040 973-7632569
7 Berkshire Way, Milford, NJ 08848 908-9957177 908-7827394
20 Sleepy Hollow Dr, Flemington, NJ 08822 908-7827394 908-7632569
7 Berkshire Way, Milford, NJ 08848 908-7639511
Work
Position:
Healthcare Support Occupations
Education
Degree:
High school graduate or higher
Mentions for Ralph T Doyle
Publications & IP owners
Wikipedia
Keith Doyle (Politician)
Keith Ralph Doyle (born 10 December 1924) is an Australian politician. He was a Liberal Party of Australia member of the New South Wales Legislative ...
Us Patents
Treating Metabolic Syndrome With Fenofibrate
US Patent:
2006008, Apr 20, 2006
Filed:
Apr 22, 2005
Appl. No.:
11/111971
Inventors:
Ralph Doyle - Milford NJ, US
Douglas Kling - Parisippany NJ, US
Roelof Rongen - Caliton NJ, US
Keith Rotenberg - Danville NJ, US
Douglas Kling - Parisippany NJ, US
Roelof Rongen - Caliton NJ, US
Keith Rotenberg - Danville NJ, US
International Classification:
A61K 31/192
A61K 9/48
A61K 9/20
A61K 9/48
A61K 9/20
US Classification:
424451000, 424464000, 514571000
Abstract:
A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment.
Statin And Omega-3 Fatty Acids For Reduction Of Apo-B Levels
US Patent:
2008008, Apr 10, 2008
Filed:
Sep 7, 2007
Appl. No.:
11/851867
Inventors:
Roelof M.L. Rongen - Califon NJ, US
Robert A. Shalwitz - Bexley OH, US
Douglas Kling - Parsippany NJ, US
Ralph T. Doyle - Milford NJ, US
Robert A. Shalwitz - Bexley OH, US
Douglas Kling - Parsippany NJ, US
Ralph T. Doyle - Milford NJ, US
Assignee:
Reliant Pharmaceuticals, Inc. - Liberty Corner NJ
International Classification:
A61K 31/20
A61K 31/225
A61K 31/35
A61K 31/40
A61K 31/405
A61K 31/47
A61K 31/505
A61P 3/00
A61K 31/225
A61K 31/35
A61K 31/40
A61K 31/405
A61K 31/47
A61K 31/505
A61P 3/00
US Classification:
514275, 514311, 514415, 514423, 514460, 514548, 514560
Abstract:
Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.